Back to Search
Start Over
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML)
- Source :
- Web of Science
- Publication Year :
- 2014
- Subjects :
- Tipifarnib, Bortezomib, Acute Myeloid Leukemia
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Web of Science
- Accession number :
- edsair.dedup.wf.001..e6728e0b7b027f174a58fb25e455639e